BACKGROUND: No curative therapy is currently available for locally advanced or metastatic prostate cancer. Oncolytic viruses represent a novel class of therapeutic agents that demonstrates no cross-resistance with existing approaches and can therefore be combined with conventional treatment modalities. Measles virus strains deriving from the Edmonston (MV-Edm) vaccine strain have shown considerable oncolytic activity against a variety of solid tumers and hematologic malignancies. In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer. METHODS: The susceptibility of prostate cancer cell lines (PC-3, DU-145, and LNCaP) to measles virus infection was demonstrated using an MV-Edm derivative expressing green fluorescent protein (GFP). MV-Edm replication in prostate cancer cell lines was assessed by one step viral growth curves. The oncolytic effect of an MV-Edm strain engineered to express the human carcinoembryonic antigen (CEA) was demonstrated in vitro by MTT assays and in vivo in subcutaneous PC-3 xenografts. CEA levels were quantitated in cell supernatants and mouse serum samples. RESULTS: Recombinant MV-Edm strains can effectively infect, replicate in and kill prostate cancer cells. Intratumoral administration of MV-CEA at a total dose of 6 x 10(6) TCID50 resulted in statistically significant tumor growth delay (P = 0.004) and prolongation of survival (P = 0.001) in a subcutaneous PC-3 xenograft model. Viral growth kinetics paralleled CEA production. CONCLUSIONS: MV-CEA has potent antitumor activity against prostate cancer cell lines and xenografts. Viral gene expression during treatment can be determined by monitoring of CEA levels in the serum; the latter could allow dose optimization and tailoring of individualized treatment protocols. Copyright 2008 Wiley-Liss, Inc.
BACKGROUND: No curative therapy is currently available for locally advanced or metastatic prostate cancer. Oncolytic viruses represent a novel class of therapeutic agents that demonstrates no cross-resistance with existing approaches and can therefore be combined with conventional treatment modalities. Measles virus strains deriving from the Edmonston (MV-Edm) vaccine strain have shown considerable oncolytic activity against a variety of solid tumers and hematologic malignancies. In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer. METHODS: The susceptibility of prostate cancer cell lines (PC-3, DU-145, and LNCaP) to measles virus infection was demonstrated using an MV-Edm derivative expressing green fluorescent protein (GFP). MV-Edm replication in prostate cancer cell lines was assessed by one step viral growth curves. The oncolytic effect of an MV-Edm strain engineered to express the humancarcinoembryonic antigen (CEA) was demonstrated in vitro by MTT assays and in vivo in subcutaneous PC-3 xenografts. CEA levels were quantitated in cell supernatants and mouse serum samples. RESULTS: Recombinant MV-Edm strains can effectively infect, replicate in and kill prostate cancer cells. Intratumoral administration of MV-CEA at a total dose of 6 x 10(6) TCID50 resulted in statistically significant tumor growth delay (P = 0.004) and prolongation of survival (P = 0.001) in a subcutaneous PC-3 xenograft model. Viral growth kinetics paralleled CEA production. CONCLUSIONS:MV-CEA has potent antitumor activity against prostate cancer cell lines and xenografts. Viral gene expression during treatment can be determined by monitoring of CEA levels in the serum; the latter could allow dose optimization and tailoring of individualized treatment protocols. Copyright 2008 Wiley-Liss, Inc.
Authors: B Roscic-Mrkic; R A Schwendener; B Odermatt; A Zuniga; J Pavlovic; M A Billeter; R Cattaneo Journal: J Virol Date: 2001-04 Impact factor: 5.103
Authors: W U Shipley; H D Thames; H M Sandler; G E Hanks; A L Zietman; C A Perez; D A Kuban; S L Hancock; C D Smith Journal: JAMA Date: 1999-05-05 Impact factor: 56.272
Authors: B Mrkic; J Pavlovic; T Rülicke; P Volpe; C J Buchholz; D Hourcade; J P Atkinson; A Aguzzi; R Cattaneo Journal: J Virol Date: 1998-09 Impact factor: 5.103
Authors: F Radecke; P Spielhofer; H Schneider; K Kaelin; M Huber; C Dötsch; G Christiansen; M A Billeter Journal: EMBO J Date: 1995-12-01 Impact factor: 11.598
Authors: Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson Journal: Neuro Oncol Date: 2015-04-02 Impact factor: 12.300
Authors: S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts Journal: Cancer Gene Ther Date: 2011-06-24 Impact factor: 5.987
Authors: Pavlos Msaouel; Ianko D Iankov; Cory Allen; Ileana Aderca; Mark J Federspiel; Donald J Tindall; John C Morris; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis Journal: Mol Ther Date: 2009-09-22 Impact factor: 11.454